126 related articles for article (PubMed ID: 36963438)
21. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity
Xu X; Wang Q; Shen L; Shen Y; Liu H; Liu Y; Yang Z; Hoffman RM; Feng W
Anticancer Res; 2024 Apr; 44(4):1399-1407. PubMed ID: 38538004
[TBL] [Abstract][Full Text] [Related]
23. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.
Chen J; Hai Y; Hu Q; Chen C; Jiang X; Gao Y
Pharm Res; 2023 Mar; 40(3):689-699. PubMed ID: 36539669
[TBL] [Abstract][Full Text] [Related]
24. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
25. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
26. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma.
Tang L; Yu W; Wang Y; Li H; Shen Z
Clin Transl Oncol; 2019 Dec; 21(12):1624-1633. PubMed ID: 30963468
[TBL] [Abstract][Full Text] [Related]
27. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
[TBL] [Abstract][Full Text] [Related]
28. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Wang J; Liu X; Hong Y; Wang S; Chen P; Gu A; Guo X; Zhao P
J Exp Clin Cancer Res; 2017 Jul; 36(1):96. PubMed ID: 28716053
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of anlotinib in thyroid cancer.
Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
[TBL] [Abstract][Full Text] [Related]
31. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
32. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
33. Mitigation of acute radiation-induced brain injury in a mouse model using anlotinib.
Gao XH; Zheng J; Ma L; Ma LB; Zhai YJ; Yang FF; Wang SJ; Fan QS; Wen J; Wang HL; Wu XH; Chen SS; Liu CM
Ann Palliat Med; 2021 Jan; 10(1):312-322. PubMed ID: 33545766
[TBL] [Abstract][Full Text] [Related]
34. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase.
Li W; Liu J; Fu W; Zheng X; Ren L; Liu S; Wang J; Ji T; Du G
J Exp Clin Cancer Res; 2018 Jul; 37(1):132. PubMed ID: 29970196
[TBL] [Abstract][Full Text] [Related]
35. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
37. CC12 Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Lines and Mouse Xenograft Model.
Fann LY; Shih JH; Tseng JH; Huang HS; Hsiao SH
Molecules; 2020 Apr; 25(8):. PubMed ID: 32295275
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
39. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer.
Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P
Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684
[TBL] [Abstract][Full Text] [Related]
40. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
